Akers Biosciences Commercializes New App-Enabled Tests for Health and Wellness Industry and Consumers
October 06 2015 - 7:00AM
Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ("Akers Bio" or
the "Company"), a medical device company focused on reducing the
cost of healthcare through faster, easier diagnostics, announces
that all development specifications have been finalized and
production has commenced for its two transformational breath tests
designed for the health and wellness industry and consumers.
Akers Bio is launching the BreathScan OxiChek™ ("OxiChek") and
BreathScan KetoChek™ ("KetoChek") tests this week at the Supply
Side West conference in Las Vegas, Nevada. The conference focuses
on dietary supplements and sports nutrition, two key markets for
these new products.
OxiChek is the first disposable breath test to rapidly determine
levels of oxidative stress (free radicals) in the body. OxiChek
measures the most abundant free radicals including superoxides,
hydrogen peroxide and aldehydes – unlike some pre-existing devices
which measure only one. Frequent use of OxiChek may help consumers
and professional clients manage and adhere to their regimen of
nutritional supplementation for management of oxidative stress,
which is implicated in many diseases, including cardiac, cancer and
arthritic diseases.
KetoChek, and the Company's non-quantitative version, METRON®,
are the only disposable breath-based diagnostic devices that
rapidly determine if the subject is in the optimal fat-burning
state for weight loss, known as ketosis. Achieving a state of
ketosis – as indicated by the measure of breath ketones – is a goal
of many individuals following low carbohydrate diets. KetoChek is a
simple, non-invasive test to identify, track and quantitatively
monitor breath ketones for individuals interested in maximizing
weight loss.
OxiChek and KetoChek work with the new bluetooth-enabled reading
device, BreathScan Lync™ and associated BreathScan™ mobile app, to
enable consumers and professional users to monitor trends in
critical metabolic processes via their mobile device. Clinicians,
suppliers of nutritional supplements and diet plans, as well as
health coaches in fitness centers, can now monitor and adjust the
progress of their clients more effectively by utilizing the
Company's products.
"The response to the Akers Wellness products has been
overwhelmingly positive," said Raymond F. Akers, Jr. PhD,
Co-founder and Executive Chairman. "We launched our first product,
METRON®, into this market last month, including through the Amazon
marketplace. Now, the Company is expanding its market reach through
our efforts at Supply Side West, targeting multi-level marketing
companies in the nutraceutical business, fitness and weight loss
centers, chiropractors, and anti-aging medicine physicians. The
Company is aggressively seeking distribution into these market
segments," continued Dr. Akers.
"We believe that consumers are increasingly looking for
personalized health, and that the BreathScan platform will provide
the footprint for the Company to enter into the new era of digital
medicine. Our new health and wellness products are poised to make
an impact now as we commence production and will begin shipping
this quarter. Health and wellness is a very large market segment
globally and our aim is to become a significant player in this
space. Whether in health and wellness or in medical diagnostics,
our faster, easier diagnostic tests provide information that makes
lives better," added Dr. Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target," "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Oct 2023 to Oct 2024